A team of scientists in Israel says they'll likely have discovered a cure for cancer in the next year.
But Len Lichtenfeld, MD, chief medical officer of the ACS, said that "we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure".
The new treatment called MuTaTo (multi-target toxin) is more like a cancer antibiotic, said Accelerated Evolution Biotechnologies CEO Dr. Ilan Morad.
"We believe we will offer in a year's time a complete cure for cancer", Aridor told the paper. "Our solution will be both generic and personal".
Read the full Jerusalem Post story here. The Post reports the drug is based on SoAP technology, which involves the introduction of DNA coding for a protein. Also, it's very important to know that cancer is not just one disease. Unlike 2018 Nobel Prize-winning scientists George Smith and Gregory Winter, who used phage display to evolve new proteins or antibodies, the Israelis are producing peptides, which Morad says are better equipped for the job because they are smaller, less expensive and less hard to manage. Now the scientists who came up with this say that cancer cells are killed off using a multiprong approach - which is a combination of cancer-targeting peptides and a strong toxin.
McConnell warns against leaving Syria and Afghanistan ‘too hastily’
However, US officials acknowledge the potential for ISIS to regain power. "Thousands of ISIS fighters remain in Syria". President Donald Trump last month announced he was ordering a full withdrawal of the 2,000 U.S. troops from Syria.
"We make sure that the treatment is not affected by the mutations; the cancer cells can mutate in such a way that the cancer discards the targeted receptors". They fail because that target mutates, changing to divide and spread and avoid attack.
"The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used", Morad continued. "Instead of attacking the receivers one at a time, we attack the receivers three at a time; even cancer can not mutate three receptors at the same time".
Morad said MuTaTo is also strong enough to both destroy stem cells and penetrate where other drugs can not reach. The experiment showed inhibited human cancer cell growth and had no effect on healthy mice cells, according to the paper.
Aridor said the company's first target is lung cancer and that it's working on others.